Considerations in Multiple Myeloma: Stem Cell Mobilization
Released:
8/31/2009
Expires:
8/31/2010
Faculty
Sagar Lonial, MD
Associate Professor of Hematology and Oncology
Emory University
Atlanta, GA
William Bensinger, MD
Director, Autologous Stem Cell Transplant Program
Division of Oncology
Fred Hutchinson Cancer Research Center
University of Washington
Seattle, WA
Beth Faiman, RN, MSN, APRN, BC, AOCN
Cleveland Clinic
Taussig Cancer Institute
Cleveland, OH
Helen Leather, BPharm, BCPS
Clinical Pharmacy Specialist
BMT/Leukemia
Shands at the University of Florida
Gainesville, FL
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with multiple myeloma (MM).
Target Audience
This activity was developed for physicians, nurses, and pharmacists.
Educational Objectives
At the completion of this activity participants should be able to:
- Explain how various agents and combination regimens used in induction regimens for multiple myeloma (MM) may affect stem cell mobilization
- Describe the safety and efficacy of standard agents used for stem cell mobilization in patients withMM
- Interpret data from clinical trials evaluating novel approaches to stem cell mobilization as reported at the 2008 ASH meeting
Agenda - 1 hour
• Articles/Commentaries: 45 minutes
• Evaluation/Post-Test: 15 minutes
Physician Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.0 contact hour.
Registered Pharmacy Designation
 MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 468-999-09-027-H01-P.
Instructions for Credit
There is no fee for this activity. To receive credit, participants must first take the pretest for this activity. After reading this CE activity in its entirety, participants must complete the posttest and evaluation. The pretest, posttest, and evaluation can be completed online at www.mlicme.org/p09005.html. Upon completion of the evaluation and scoring a 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the Certificate for your records.
For questions regarding the accreditation of this activity, please contact Medical Learning Institute at (609) 333-1693 or cgusack@mlicme.org.
Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity will disclose the existence of any financial interest and/or relationship(s) theymight havewith themanufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner
or Manager | Company | Reported Financial
Relationship |
| Amanda Glazar, PhD | Global | Nothing to disclose |
| Hao Vu, RPh | MLI | Nothing to disclose |
| Ryan Sims, CRNA, MS | MLI | Nothing to disclose |
| Karen Cooksey | COEXM | Nothing to disclose |
| Susan Berry | COEXM | Nothing to disclose |
Faculty Disclosures
Sagar Lonial, MD is a consultant for Amgen, Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Millennium.
William Bensinger, MD has done clinical research for AstraZeneca, Celgene, Geron, Millennium, and Novartis, is on the speaker's bureau for Celgene, and is on the advisory board for Millennium.
Beth Faiman, RN, MSN, APRN, BC, AOCN is on the speaker's bureau for Millennium and Celgene.
Helen Leather, BPharm, BCPS is a consultant for Genzyme and Novartis.
*Content will include non-FDA-approved uses.
Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Sponsor Statement
This activity is jointly sponsored by Global Education Group and Medical Learning Institute, Inc.
Content development and logistics for this activity provided by Center of Excellence Media, LLC.
 
Commercial Support Acknowledgement
This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc.
Technology Requirements
|
|
